These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

714 related articles for article (PubMed ID: 31178870)

  • 21. Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma.
    Posey AD; Schwab RD; Boesteanu AC; Steentoft C; Mandel U; Engels B; Stone JD; Madsen TD; Schreiber K; Haines KM; Cogdill AP; Chen TJ; Song D; Scholler J; Kranz DM; Feldman MD; Young R; Keith B; Schreiber H; Clausen H; Johnson LA; June CH
    Immunity; 2016 Jun; 44(6):1444-54. PubMed ID: 27332733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical evaluation of an
    Kelly VJ; Wu ST; Gottumukkala V; Coelho R; Palmer K; Nair S; Erick T; Puri R; Ilovich O; Mukherjee P
    Theranostics; 2020; 10(15):6946-6958. PubMed ID: 32550914
    [No Abstract]   [Full Text] [Related]  

  • 23. Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma.
    Supimon K; Sangsuwannukul T; Sujjitjoon J; Phanthaphol N; Chieochansin T; Poungvarin N; Wongkham S; Junking M; Yenchitsomanus PT
    Sci Rep; 2021 Mar; 11(1):6276. PubMed ID: 33737613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells.
    Xiong W; Chen Y; Kang X; Chen Z; Zheng P; Hsu YH; Jang JH; Qin L; Liu H; Dotti G; Liu D
    Mol Ther; 2018 Apr; 26(4):963-975. PubMed ID: 29503199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.
    Hu B; Zou Y; Zhang L; Tang J; Niedermann G; Firat E; Huang X; Zhu X
    Hum Gene Ther; 2019 Apr; 30(4):446-458. PubMed ID: 29706119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer.
    Liu L; Wang Y; Miao L; Liu Q; Musetti S; Li J; Huang L
    Mol Ther; 2018 Jan; 26(1):45-55. PubMed ID: 29258739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level.
    Song DG; Ye Q; Poussin M; Chacon JA; Figini M; Powell DJ
    J Hematol Oncol; 2016 Jul; 9(1):56. PubMed ID: 27439908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer.
    Hu Z
    Sci Rep; 2020 Feb; 10(1):2815. PubMed ID: 32071339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer.
    Anderson KG; Voillet V; Bates BM; Chiu EY; Burnett MG; Garcia NM; Oda SK; Morse CB; Stromnes IM; Drescher CW; Gottardo R; Greenberg PD
    Cancer Immunol Res; 2019 Sep; 7(9):1412-1425. PubMed ID: 31337659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells.
    You F; Jiang L; Zhang B; Lu Q; Zhou Q; Liao X; Wu H; Du K; Zhu Y; Meng H; Gong Z; Zong Y; Huang L; Lu M; Tang J; Li Y; Zhai X; Wang X; Ye S; Chen D; Yuan L; Qi L; Yang L
    Sci China Life Sci; 2016 Apr; 59(4):386-97. PubMed ID: 26961900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer.
    Dees S; Ganesan R; Singh S; Grewal IS
    Mol Cancer Ther; 2020 Dec; 19(12):2409-2421. PubMed ID: 33087511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting Stage-Specific Embryonic Antigen 4 (SSEA-4) in Triple Negative Breast Cancer by CAR T Cells Results in Unexpected on Target/off Tumor Toxicities in Mice.
    Pfeifer R; Al Rawashdeh W; Brauner J; Martinez-Osuna M; Lock D; Herbel C; Eckardt D; Assenmacher M; Bosio A; Hardt OT; Johnston ICD
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel chimeric antigen receptor redirecting T-cell specificity towards CD26
    Zhou S; Li W; Xiao Y; Zhu X; Zhong Z; Li Q; Cheng F; Zou P; You Y; Zhu X
    Leukemia; 2021 Jan; 35(1):119-129. PubMed ID: 32317776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
    Majzner RG; Theruvath JL; Nellan A; Heitzeneder S; Cui Y; Mount CW; Rietberg SP; Linde MH; Xu P; Rota C; Sotillo E; Labanieh L; Lee DW; Orentas RJ; Dimitrov DS; Zhu Z; Croix BS; Delaidelli A; Sekunova A; Bonvini E; Mitra SS; Quezado MM; Majeti R; Monje M; Sorensen PHB; Maris JM; Mackall CL
    Clin Cancer Res; 2019 Apr; 25(8):2560-2574. PubMed ID: 30655315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.
    Magee MS; Abraham TS; Baybutt TR; Flickinger JC; Ridge NA; Marszalowicz GP; Prajapati P; Hersperger AR; Waldman SA; Snook AE
    Cancer Immunol Res; 2018 May; 6(5):509-516. PubMed ID: 29615399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CAR-T Cells for Cancer Treatment: Current Design and Next Frontiers.
    Picanço-Castro V; Swiech K; Malmegrim KCR; Covas DT
    Methods Mol Biol; 2020; 2086():1-10. PubMed ID: 31707664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies.
    Niu Z; Wu J; Zhao Q; Zhang J; Zhang P; Yang Y
    Front Immunol; 2024; 15():1385571. PubMed ID: 38680498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Engineering light-controllable CAR T cells for cancer immunotherapy.
    Huang Z; Wu Y; Allen ME; Pan Y; Kyriakakis P; Lu S; Chang YJ; Wang X; Chien S; Wang Y
    Sci Adv; 2020 Feb; 6(8):eaay9209. PubMed ID: 32128416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.
    Luangwattananun P; Junking M; Sujjitjoon J; Wutti-In Y; Poungvarin N; Thuwajit C; Yenchitsomanus PT
    Breast Cancer Res Treat; 2021 Feb; 186(1):25-36. PubMed ID: 33389403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.